Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity. — The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints. These two anti-amyloid...

Evidence span

Disease-modifying therapies for Alzheimer's disease: Clinical trial progress and opportunity. — The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints. These two anti-amyloid...

From Zhang Y et al. 2025, Ageing research reviews

Method & conditions

Evidence type

experimental

Method

manual state transition; placebo-controlled clinical trial where source reports control arm

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Clinical Trials as Topic; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized — Ageing research reviews 2025

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required